Effects of two personalized #dietary strategies during a 2‐year intervention in subjects with nonalcoholic #fatty #liver disease: a randomized trial

Background and objectives Nonalcoholic fatty liver disease (NAFLD) management is focused on lifestyle modifications, but long‐term maintenance is a challenge for many individuals. This study aimed to evaluate the long‐term effects of two personalized energy‐restricted dietary strategies on weight loss, metabolic and hepatic outcomes in overweight/obese subjects with NAFLD. Methods Ninety‐eight subjects from the Fatty Liver in Obesity (FLiO) study (NCT03183193) were randomly assigned to … Continue reading Effects of two personalized #dietary strategies during a 2‐year intervention in subjects with nonalcoholic #fatty #liver disease: a randomized trial

Rate This

The Tailgate Study: Differing #metabolic effects of a bout of excessive #eating and #drinking

Excess energy intake by spectators at a sporting event (i.e., a tailgate) might cause acute negative health effects. However, limited data exist regarding the effects of overeating and alcohol consumption on lipid metabolism and the potential to gain intrahepatic triacylglycerols (IHTG). We tested the hypothesis that overconsumption of food and alcohol would significantly increase both hepatic de novo lipogenesis (DNL) and IHTG. Methods Eighteen males … Continue reading The Tailgate Study: Differing #metabolic effects of a bout of excessive #eating and #drinking

Rate This

Serum hepatitis B #core‐related antigen level stratifies risk of disease progression in chronic #hepatitis B patients with intermediate viral load

Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.. ..A total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg … Continue reading Serum hepatitis B #core‐related antigen level stratifies risk of disease progression in chronic #hepatitis B patients with intermediate viral load

Rate This

Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Liver disease is highly prevalent among people with type 2 diabetes mellitus (T2DM). We evaluated the dipeptidyl peptidase-4 inhibitor linagliptin in subjects with T2DM and hepatic disorders.. ..Of the 7009 participants (56% white, 39% Asian), 574 had hepatic disorders, most commonly hepatic steatosis (60%). At week 24, adjusted mean ± standard error (SE) change in HbA1c from baseline in those with hepatic disorders was − … Continue reading Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Rate This

Physiologically increased total #bilirubin is associated with reduced risk of first #myocardial infarction: A meta-analysis and dose-response analysis

Bilirubin has potential predictive and prognostic value for myocardial infarction (MI), but the clinical evidence remains controversial. We performed this meta-analysis to systematically quantify the relationships between circulating bilirubin levels and the incidence of MI and post-MI adverse events. We searched the PubMed, Cochrane Library, Embase, and Web of Science databases for ad-hoc studies, published up to October 17, 2020, recording bilirubin before MI (predictive … Continue reading Physiologically increased total #bilirubin is associated with reduced risk of first #myocardial infarction: A meta-analysis and dose-response analysis

Rate This

#Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis

We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.. ..The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased in-hospital mortality [odds ratio=28.72, 95% confidence interval (CI): 8.99-91.73], length … Continue reading #Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis

Rate This

Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics and unaware of having NAFLD. At the visit, volunteers were … Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Rate This

Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?

The revolution of the antiviral treatment of hepatitis C virus (HCV) infection resulting in higher effectiveness came with the introduction of direct‐acting antivirals with pangenotypic regimens as a final touch. Among them, the combination of glecaprevir (GLE) and pibrentasvir (PIB) provides the opportunity for shortening therapy to 8 weeks in the majority of patients. Because of still insufficient evaluation of this regimen in the real‐world … Continue reading Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?

Rate This

JAK inhibition reduces #SARS-CoV-2 #liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Using AI we identified baricitinib as possessing anti-viral and anti-cytokine efficacy. We now show a 71% (95% CI 0.15-0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse events, including a large elderly cohort (median age 81 years). A further 48 cases with mild-moderate pneumonia recovered uneventfully. Using organotypic 3D cultures of primary human liver cells, we demonstrate that interferon-alpha-2 (IFNα2) … Continue reading JAK inhibition reduces #SARS-CoV-2 #liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Rate This

A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to receive semaglutide at a dose of 0.1 mg (80 patients), … Continue reading A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis

Rate This

Associations between #Helicobacter pylori with nonalcoholic fatty #liver disease and other metabolic conditions in Guatemala

Previous studies have suggested an association between Helicobacter pylori (H pylori) and nonalcoholic fatty liver disease (NAFLD). The aim of the current study was to examine the association in Guatemala, a region with elevated prevalences of both H pylori and NAFLD. Associations between H pylori and other metabolic conditions were also examined, as were associations between H hepaticus and H bilis and the metabolic conditions. … Continue reading Associations between #Helicobacter pylori with nonalcoholic fatty #liver disease and other metabolic conditions in Guatemala

Rate This

GES: A validated simple score to predict the risk of #HCC in patients with #HCV‐GT4‐associated advanced liver fibrosis after oral antivirals

Hepatocellular carcinoma (HCC) risk persists after hepatitis C virus (HCV) eradication with direct‐acting antivirals (DAAs), particularly in patients with cirrhosis. Identifying those who are likely to develop HCC is a critical unmet medical need. Our aim is to develop a score that offers individualized patient HCC risk prediction.. ..In the derivation cohort, the median follow‐up was 23.51 ± 8.21 months, during which 109 patients (4.7%) … Continue reading GES: A validated simple score to predict the risk of #HCC in patients with #HCV‐GT4‐associated advanced liver fibrosis after oral antivirals

Rate This